• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gemini Therapeutics Inc (NQ: GMTX )

    N/A UNCHANGED
    Last Price Updated: 3:59 PM EST, Dec 29, 2022 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Gemini Therapeutics Inc

    Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    GEMINI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. - GMTX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    GMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Gemini Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLP
    Via Business Wire
    Gemini Therapeutics and Disc Medicine Announce Merger Agreement
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Provides Corporate Update
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Provides GEM103 Program Update
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Poster Presentation at AAO 2021
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics to Participate in Upcoming Investor Conferences
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Presentation at 2nd Annual Dry AMD Therapeutic Development Summit
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 Virtual
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the Summit
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
    From Gemini Therapeutics, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.